US FDA expands approval to GSK’s Arexvy for adults aged 50-59, at increased risk
The RSV vaccine adjuvanted is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
lower respiratory tract disease
US FDA approves GSK’s Arexvy, world’s first RSV vaccine for older adults
Older adults, including those with underlying medical conditions such as diabetes and chronic heart and lung disease, are at…